Did a targeted drug help leukemia patients stay cancer-free longer after transplant?

NCT ID NCT06734585

First seen Oct 31, 2025 · Last updated May 06, 2026 · Updated 32 times

Summary

This study looked at people with a specific genetic form of acute myeloid leukemia (FLT3-mutated) whose cancer returned or didn't respond to treatment. Researchers compared those who took the drug gilteritinib after a stem cell transplant to those who received standard care, using medical records from 2015 to 2022. The goal was to see if gilteritinib helped patients stay cancer-free longer. No new treatments were given—only existing data was collected and analyzed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AU61001

    Melbourne, Australia

  • AU61002

    Melbourne, Australia

  • BR55001

    São Paulo, Brazil

  • BR55002

    Porto Alegre, Brazil

  • BR55003

    São Paulo, Brazil

  • BR55004

    Fortaleza, Brazil

  • CN86001

    Tianjin, China

  • CN86003

    Shanghai, China

  • CN86004

    Suzhou, China

  • HK852001

    Hong Kong, Hong Kong

  • KR82001

    Seoul, South Korea

  • KR82002

    Seoul, South Korea

  • KR82003

    Seoul, South Korea

  • KR82004

    Busan, South Korea

  • KR82005

    Gwangju, South Korea

  • TW88601

    Taipei, Taiwan

  • TW88602

    Tainan, Taiwan

  • TW88603

    Taichung, Taiwan

Conditions

Explore the condition pages connected to this study.